Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Kausik Ray: Efficacy and Safety of Obicetrapib in Patients With HeFH on Maximally Tolerated Statins
Kausik Ray and Stephen Nicholls
Mar 13, 2026, 11:48

Kausik Ray: Efficacy and Safety of Obicetrapib in Patients With HeFH on Maximally Tolerated Statins

Kausik Ray, Professor of Public Health at Imperial College London, Past President of European Atherosclerosis Society, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:

”Our key publication on the efficacy and safety of obicetrapib in patients with HeFH on maximally tolerated statins published in Nature Medicine. Well done, Stephen Nicholls.

Obicetrapib reduced LDL-C by ~ 36%, resulting in more patients achieving risk-based LDL-C goals and reduced Lp (a) meaningfully.
The ultimate test of this novel approach, CETPi, will come from PREVAIL.

Why it matters….. As we have shown (Hu et al., Circulation) HeFH occurs in 1:311 people globally. Our FHSC (Lancet 2021) showed globally the average age of diagnosis is 44 years, with less than 2% adults identified before the age of 18. This means that at detection, because of missed years of cholesterol exposure, 17% already have cardiovascular disease. Hence, we need to claw those years back with combination therapies. Only 2% of patients were at goal in the FHSC 2021 paper globally; we need effective, affordable treatments.

With obicetrapib expected in 2026 in Europe, we will have another tool in our arsenal to manage patients with HeFH.”

Title: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial

Authors: Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, John J. P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven E. Nissen, Anne C. Goldberg, Liam R. Brunham, Erin Wuerdeman, Annie L. Neild, Douglas Kling, Andrew Hsieh, Julie Butters, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L. Catapano, Michael Szarek, Violeta Balinskaite, Michael H. Davidson

Read the Full Article on Nature Medicine

Kausik Ray: Efficacy and Safety of Obicetrapib in Patients With HeFH on Maximally Tolerated Statins

Stay updated with Hemostasis Today.

Adam J. Nelson Alberico L Catapano Andrew Hsieh Ann Marie Navar Anne C. Goldberg Annie L. Neild Brian A Ference BROOKLYN Trial Christie M. Ballantyne Douglas Kling Erin Wuerdeman Familial hypercholesterolemia Health HeFH HeFH Patients Hematology Hemostasis Hemostasis Today Hypercholesterolemia Imperial College London John J. P. Kastelein Julie Butters Kausik K. Ray Liam R. Brunham Maciej Banach Marc Ditmarsch Medicine Michael H. Davidson Michael Szarek Nature Medicine Obicetrapib Roxana Mehran Stephen J Nicholls Steven E. Nissen thrombosis Ulrich Laufs Violeta Balinskaite
NewsFeed